title: Inhibition of immune functions by antiviral drugs.
abstract: Immune functions were evaluated in vitro for PBMC isolated from healthy donors and cultured with the antiviral agents, 3'-azido-3'-deoxythymidine (AZT), ribavirin, ganciclovir, 2'3'-dideoxyinosine (ddI), or acyclovir. To identify methods for assessing the effects of antiviral drugs on immune cells, the PBMC response to mitogens, Con A, or phytohemagglutinin was evaluated from measurements of [3H]thymidine and [14C]-leucine incorporation, cell growth, cellular RNA, DNA, and protein levels, and the PBMC proliferative cycle (i.e., progression from G0----G1----S----G2 + M). At clinically relevant concentrations, AZT, ribavirin, or ganciclovir diminished PBMC responsiveness to mitogen. The numbers of proliferating cells in G1, S, and G2 + M phases of the cell cycle, DNA content, and [3H]thymidine uptake were decreased in cultures treated with AZT, ribavirin, or ganciclovir. AZT or ribavirin but not ganciclovir reduced RNA and protein in the cultures and inhibited cell growth. Whereas AZT, ribavirin, or ganciclovir were antiproliferative, ddI or acyclovir had little, if any, effect on PBMC mitogenesis. The inhibitory effects of antivirals on immune cells may contribute to the immune deterioration observed in patients following prolonged use of the drugs.
authors.affiliation: Laboratory of Infectious Diseases, Dana-Farber Cancer Institute, Boston, Massachusetts 02115.
authors.forename: W
authors.initials: W
authors.lastname: Heagy
authors.forename: C
authors.initials: C
authors.lastname: Crumpacker
authors.forename: P A
authors.initials: PA
authors.lastname: Lopez
authors.forename: R W
authors.initials: RW
authors.lastname: Finberg
mesh_terms: D000212:Acyclovir / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis; D016049:Didanosine / Q000494:pharmacology; D015774:Ganciclovir / Q000494:pharmacology; D006801:Humans; D007109:Immunity / Q000187:drug effects*; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects*; D011506:Proteins / Q000378:metabolism; D012254:Ribavirin / Q000494:pharmacology; D015215:Zidovudine / Q000494:pharmacology
chemical_list: D000998:Antiviral Agents; D011506:Proteins; D003208:Concanavalin A; D012254:Ribavirin; D015215:Zidovudine; D004247:DNA; D016049:Didanosine; D015774:Ganciclovir; D000212:Acyclovir